AMO-01

Phase 2Small molecule

AAlexander Kolevzon

AMO-01 is one of 5 small molecule programs targeting Phelan-McDermid syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phelan-Mcdermid SyndromeActive, not recruiting

Phelan-Mcdermid SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Phelan-Mcdermid Syndrome

#DrugCompanyPhaseTrials

Pitocin

RRetrophin

Phase 2

1 2

Growth Hormone

Pfizer

Phase 2

1 3

Genotropin

EMD Serono

Phase 2

—4

NNZ-2591

NNeuren Pharmaceuticals Limited

Phase 3

3 5

AMO-01

AAlexander Kolevzon

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Phelan-McDermid syndrome1 trial

AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy

Completed·AAlexander Kolevzon·Phase 2·NCT03493607·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AMO-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMO-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMO-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alexander Kolevzon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlexander Kolevzon

AMO-01

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Phelan-McDermid syndrome1 trial

References

Drug Info

Quick Facts

Related News